Peer-reviewed veterinary case report
Vaccine using vaccinia vector protects dogs from visceral
By Ramos, I et al.·Published in Vaccine·2008·Centro de Investigaciones Bioló, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
- Species:
- dog
Plain-English summary
A group of dogs was vaccinated to protect against canine visceral leishmaniasis, a serious disease caused by a parasite. The dogs received an initial DNA vaccine followed by a booster shot with a modified virus. This vaccination method successfully triggered a strong immune response, which helped prevent symptoms of the disease. The vaccinated dogs showed fewer signs of infection and had a more active immune system in the areas affected by the parasite. Overall, the study suggests that this vaccination approach could be effective in protecting dogs from this serious illness.
People also search for: dog leishmaniasis vaccine · canine visceral leishmaniasis symptoms · dog vaccination for leishmaniasis
Abstract
Leishmaniasis caused by Leishmania infantum is a severe endemic disease in the Mediterranean basin, being domestic dogs the main reservoir of the disease that plays a key role in the transmission to humans. Studies on vaccines against canine leishmaniasis, aimed to modify the T cell repertoire, have advanced in recent years. LACK vaccination assays, using protein or DNA vectors, show protection against cutaneous L. major infections by redirecting the early IL-4 responses to a protective Th1 response. The aim of this study was to define the effectiveness and type of immune response in a canine visceral leishmaniasis model of two poxvirus vectors (Western reserve strain, WR and modified vaccinia virus Ankara, MVA) expressing the LACK protein of L. infantum in prime/boost vaccination protocols. The results obtained showed that dog vaccination priming with DNA-LACK followed by a booster with MVA-LACK or rVV-LACK triggered a Th1 type of immune response, leading to protection against canine visceral leishmaniasis. This protection correlated with absence of visceral leishmaniasis symptoms, lower Leishmania-specific antibodies, higher degree of T cell activation in Leishmania-target organs and higher synthesis of Th1 cytokines. In addition, we found that dogs boosted with the non-replicative virus show less VL symptoms and higher degree of T cell activation, providing evidences for a clear advantage of MVA-LACK as a vaccination vector against canine visceral leishmaniasis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/18093705/